eIF4A i28, an inhibitor of the eukaryotic initiation factor-4A (eIF4A) with an IC50 of 8.60 uM in an eIF4A ATPase assay, effectively reduces the viability of BJAB Burkitt lymphoma cells, as indicated by an EC50 of 0.46 uM in a CellTiter-Glo (CTG) luminescence cell viability assay. This compound functions as an RNA-competitive, ATP-uncompetitive eIF4A inhibitor.